为治疗耐药疟疾而开发和评价基于新的阿美西宁持续释放配方,用于治疗耐药疟疾
Yijie Wang1, Xinyu Yu2,3, Xinyu Zhang2,3
1The Key Laboratory of Synthetic and Biological Colloids, Ministry of Education, School of Chemical and Material Engineering, Jiangnan University, Wuxi, China.
mBio
|January 12, 2026
概括
一种基于基的新型纳米载体显著提高了素 (ART) 溶解度,并延长了其半衰期,提高了对抗药物耐药疟疾寄生虫的疗效. 这种配方为克服ART耐药性和改善患者治疗结果提供了一个有希望的解决方案.
科学领域:
- 生物材料科学 生物材料科学
- 制药科学 制药科学
- 寄生虫学的寄生虫学
背景情况:
- 素 (ART) 对于疟疾治疗至关重要,但其溶解性差,半衰期短,导致耐药性和治疗失败.
- 杆菌 (Plasmodium falciparum) 的耐药性是一个日益严重的全球健康问题,需要改进治疗策略.
- 现有的ART限制阻碍了有效的疟疾控制,推动了对先进药物输送系统的需求.
研究的目的:
- 开发使用基于eiN的纳米载体的阿尔特美西宁持续释放配方.
- 提高ART的水溶性,并延长其体内半衰期,以提高抗疟疾功效.
- 为了评估纳米配方对抗药物耐药性Plasmodium falciparum菌株的有效性.
主要方法:
- 在天然玉米蛋白 (zein) 中封装ART,以创建生物相容的纳米载体.
- 在体外评估ART溶解性,持续释放概况以及在酸性和基本性环境中的分散性.
- 在试验室中对纳米配方对抗ART耐药P.falciparum菌株的抑制作用的评估,使用环生存和复发试验.
- 在动物疟疾和人性化红细胞小鼠模型中的体内研究,以评估药理动力学和治疗疗效.
主要成果:
- 基于eiN的纳米载体配方实现了ART水溶性的200倍增加.
- 在实验室中证实了从纳米载体中持续释放ART,保持治疗度.
- 该纳米配方在体外表现出对抗ART耐药P.falciparum菌株的强有力的活性.
- 在体内研究显示,ART半衰期延长,寄生病减少,并预防复发,克服ART耐药性.
结论:
- 基于Zain的纳米载体有效地解决了ART的可溶性和药理动力学限制.
- 该纳米配方在对抗耐药疟疾方面具有显著的潜力.
- 这一策略为优化基于ART的抗疟疾疗法提供了一种有希望的方法,以改善临床结果.
相关概念视频
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:29Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...